Clinical Trials

Sosei Group Corporation announces that its immuno-oncology collaboration with AstraZeneca is progressing well. The first patient has been dosed in an expansion cohort in the Phase 1b…
Read More...

Xcovery announced the initiation of its Phase 2 clinical trial of ensartinib (X-396), the company’s lead anaplastic lymphoma kinase (ALK) drug candidate, in patients with advanced…
Read More...

ORICULA THERAPEUTICS, LLC., a biotech company introducing medications to preserve hearing and balance, announced FDA permission to begin volunteer human testing for safety,…
Read More...

Shield Therapeutics plc announces top-line results from its AEGIS-CKD pivotal Phase III study of Feraccru. Feraccru is a novel oral ferric iron therapy that has been approved and…
Read More...

Clinical-stage pharmaceutical company, Imago BioSciences developing novel therapies for hematological and inflammatory diseases asserted FDA's acceptance of their Investigational New…
Read More...

With a view to permit cancer patients access to potentially life-saving treatments, Lazarex Cancer Foundation's push for FDA issuing new FDA guidelines was taken into account by the…
Read More...

Panacea Pharmaceuticals, a clinical stage bio-pharmaceutical company developing novel biologically--targeted cancer therapies and diagnostics declared the enrollment of patient in an…
Read More...

It is noteworthy that TVA Medical's everlinQ endoAVF System exhibited positive Clinical results using the everlinQ endoAVF System. An international meta-analysis of clinical experience…
Read More...

FDA permits a Phase II Clinical Trial in 60 stroke patients, NuvOx Pharma announced FDA approval to proceed to test its investigational drug product, dodecafluoropentane emulsion…
Read More...

Hisamitsu Pharmaceutical in collaboration with U.S subsidiary, Novel Pharmaceuticals, Inc declares that the the transdermal patch for the treatment of schizophrenia Development code:…
Read More...

Phase II ‘basket’ clinical trial of PB272 (neratinib) in patients with tumors harboring HER2 or HER3 mutations results were declared by Puma Biotechnology as published in the journal…
Read More...

Vertex Pharmaceuticals selected VX-659 and VX-445 for Phase 3 development as part of two different triple combination regimens fir people with cystic fibrosis. Phase 2 data was…
Read More...

Global provider of cloud-based technology and data analytics for clinical research, Medidata and Syapse partner to transform Oncology Clinical Trials for the age of precision medicine.…
Read More...

Novartis declared results from ELIANA Clinical Trial of kymriah in refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.  Kymriah claimed to become one…
Read More...

Clinical-stage biotechnology company,devoted to treating inflammation and inborn errors of metabolism, Aldeyra Therapeutics enrolled first patient in a Phase 2b Clinical Trial of …
Read More...

Mallinckrodt plc affirmed enrolling first patient in the company's Phase 4, multi center, randomized, double-blind, placebo-controlled pilot study to facilitate evaluation of the…
Read More...

Takeda Pharmaceutical company Limited asserted that the U.S Food and Drug Administration has extended Fast Track designation to TAK-426 i.e Takeda's Zika virus vaccine candidate. …
Read More...

European Organisation for Research and Treatment of Cancer (EORTC) and Foundation Medicine collaborate to ascertain eligibility of patients for oncology clinical Trials of  Foundation…
Read More...

Clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, SillaJen declared the commencement of Phase 1/2 clinical trial of…
Read More...

Aradigm Corporation asserted that it received a Complete Response Letter from the US Food and Drug Administration regarding its New Drug Application (NDA) for Linhaliq for treating …
Read More...